[go: up one dir, main page]

AR024334A1 - Vacunas adn para animales de compania y de deporte - Google Patents

Vacunas adn para animales de compania y de deporte

Info

Publication number
AR024334A1
AR024334A1 ARP000102879A ARP000102879A AR024334A1 AR 024334 A1 AR024334 A1 AR 024334A1 AR P000102879 A ARP000102879 A AR P000102879A AR P000102879 A ARP000102879 A AR P000102879A AR 024334 A1 AR024334 A1 AR 024334A1
Authority
AR
Argentina
Prior art keywords
company
improvement
dna vaccines
dna vaccination
sports animals
Prior art date
Application number
ARP000102879A
Other languages
English (en)
Inventor
Jean-Charles Fischer Laurent
Barzu-Le Roux Simona
Jean-Christophe
Adonnet Francis
Original Assignee
Merial Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9907604A external-priority patent/FR2794648B1/fr
Application filed by Merial Sas filed Critical Merial Sas
Publication of AR024334A1 publication Critical patent/AR024334A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/265—Infectious rhinotracheitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/175—Canine distemper virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/27—Equine rhinopneumonitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Mejora de la eficacia y de la proteccion inducida por la vacunacion ADN contra los virus de la familia de los Paramyxoviridae y contra los virus herpes, enlos animales de companía y de deporte. La mejora de la vacunacion ADN se lleva a cabo o bienpo r la formulacion de la vacuna con un lípido cationico quecontiene una sal de amonio cuaternario, DMRIE, o bien por modificaciones en la secuencia nucleotídica que codifica al antígeno de interés, y/o por insercionesde intrones y/o inserciones desecu encias nucleotídicas que codifican para péptidos senal, o bien por la adicion de GM-CSF, o bien por sus combinaciones.Vacunas así obtenidas.
ARP000102879A 1999-06-10 2000-06-12 Vacunas adn para animales de compania y de deporte AR024334A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9907604A FR2794648B1 (fr) 1999-06-10 1999-06-10 Vaccins adn pour animaux de compagnie et de sport
US14449099P 1999-07-19 1999-07-19

Publications (1)

Publication Number Publication Date
AR024334A1 true AR024334A1 (es) 2002-10-02

Family

ID=26234993

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000102879A AR024334A1 (es) 1999-06-10 2000-06-12 Vacunas adn para animales de compania y de deporte

Country Status (11)

Country Link
EP (1) EP1185662B1 (es)
JP (1) JP2003502345A (es)
KR (1) KR100768114B1 (es)
AR (1) AR024334A1 (es)
AU (1) AU782154C (es)
BR (1) BR0011732B1 (es)
CA (1) CA2375320C (es)
CZ (1) CZ20014392A3 (es)
NZ (1) NZ515993A (es)
PL (1) PL210451B1 (es)
WO (1) WO2000077043A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804028B1 (fr) * 2000-01-21 2004-06-04 Merial Sas Vaccins adn ameliores pour animaux de rente
FR2823222B1 (fr) 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
FR2825280B1 (fr) * 2001-06-01 2005-04-15 Merial Sas Vaccination contre le virus de l'immunodeficience feline
ES2417019T3 (es) 2003-11-13 2013-08-05 University Of Georgia Research Foundation, Inc. Procedimiento de caracterización del virus de la enfermedad de la bursitis infecciosa
ATE461710T1 (de) 2005-04-25 2010-04-15 Merial Ltd Nipah-virus-impfstoffe
JP5275803B2 (ja) * 2005-09-16 2013-08-28 メリアル リミテッド 凍結乾燥ワクチン用安定剤
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
US9789129B2 (en) 2008-04-17 2017-10-17 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
AU2010249330B2 (en) 2009-05-22 2015-11-05 Genocea Biosciences Inc. Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
US20130197612A1 (en) * 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
AU2011336894B2 (en) 2010-11-24 2016-11-17 Genocea Biosciences, Inc. Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
AU2012340712B2 (en) 2011-11-23 2017-09-14 Genocea Biosciences, Inc. Nucleic acid vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
EP2861245B1 (en) 2012-06-15 2019-10-16 PDS Biotechnology Corporation Cationic lipid vaccine compositions and methods of use
CN105101991A (zh) 2012-09-21 2015-11-25 Pds生物科技公司 改进的疫苗组合物和使用方法
CN104164409A (zh) * 2014-07-18 2014-11-26 中国人民解放军军事医学科学院军事兽医研究所 含有犬gmcsf基因的重组犬瘟热病毒及其制备方法
CN104958283A (zh) * 2015-06-02 2015-10-07 北京盛大康成医疗技术有限公司 弱碱性皮肤粘膜清洗消毒组合物及其制造方法和用途
US11612652B2 (en) 2015-11-13 2023-03-28 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
KR101694676B1 (ko) 2015-12-10 2017-01-10 우진 비앤지 주식회사 말 선역 질병원인 국내 분리 스트렙토코커스 이콰이 균주 및 이를 포함하는 백신
EP3519427A4 (en) 2016-09-28 2020-03-11 Genocea Biosciences Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF HERPES
US20220054616A1 (en) 2019-01-04 2022-02-24 Boehringer Ingelheim Animal Health USA Inc. Attenuated Bordetella Bronchiseptica Strains, Oral Vaccines Containing the Attenuated Strains, and Methods of Making & Use Thereof
CN115605497A (zh) * 2019-10-09 2023-01-13 梅约医学教育与研究基金会（Us） 犬瘟热病毒血凝素和融合多肽

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338683A (en) * 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
WO1994027435A1 (en) * 1993-06-01 1994-12-08 Life Technologies, Inc. Genetic immunization with cationic lipids
ES2293639T3 (es) * 1994-03-30 2008-03-16 Connaught Technology Corporation Secuencias de nucleotidos y aminoacidos de los virus gb, gc y gd del herpes canino y sus usos.
CA2214029A1 (en) * 1995-04-25 1996-10-31 Magda Marquet Single-vial formulations of dna/lipid complexes
ES2109189B1 (es) * 1996-03-14 1998-05-16 Iberica Cyanamid Vectores basados en genomas virales defectivos recombinantes y su empleo en la formulacion de vacunas.
CA2253229A1 (en) * 1996-04-29 1997-11-06 Riccardo Wittek Polynucleotide vaccine against canine distemper
FR2751223B1 (fr) * 1996-07-19 1998-12-04 Rhone Merieux Formule de vaccin polynucleotidique felin
FR2751227B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
FR2751226B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
AU1987197A (en) * 1997-03-10 1998-09-29 Heather Lynn Davis Gene delivery to mucosal epithelium for immunization or therapeutic purpose
AU1131200A (en) * 1998-10-23 2000-05-15 Heska Corporation Cationic lipid-mediated enhancement of nucleic acid immunization of cats

Also Published As

Publication number Publication date
PL352212A1 (en) 2003-08-11
EP1185662B1 (fr) 2011-03-02
KR20020012271A (ko) 2002-02-15
WO2000077043A2 (fr) 2000-12-21
KR100768114B1 (ko) 2007-10-17
EP1185662A2 (fr) 2002-03-13
BR0011732A (pt) 2002-03-05
WO2000077043A3 (fr) 2001-07-19
NZ515993A (en) 2004-04-30
PL210451B1 (pl) 2012-01-31
AU782154B2 (en) 2005-07-07
AU5540500A (en) 2001-01-02
CZ20014392A3 (cs) 2002-06-12
AU782154C (en) 2006-02-09
JP2003502345A (ja) 2003-01-21
BR0011732B1 (pt) 2014-02-04
CA2375320C (en) 2013-02-19
CA2375320A1 (en) 2000-12-21

Similar Documents

Publication Publication Date Title
AR024334A1 (es) Vacunas adn para animales de compania y de deporte
ES2251030T3 (es) Formula de vacuna polinucleotida para el tratamiento de patologias respiratorias y reproductivas de los cerdos.
Romero et al. Single capripoxvirus recombinant vaccine for the protection of cattle against rinderpest and lumpy skin disease
ES2210548T3 (es) Formula de vacuna polinucleotidica, particularmente para el tratamiento de la patologia respiratoria en los bovinos.
EP0914442B1 (fr) Formule de vaccin polynucleotidique aviaire
ES2629860T3 (es) Vectores virales recombinantes
EP0954332B2 (fr) Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
ES2070866T3 (es) Vacunas recombinantes contra la coccidiosis.
BR9605153A (pt) Vacina de combinação para uso na proteção de galináceos contra a doença de newcastle kit de vacinação para imunizar galináceos contra a doença de newcastle e processo para a prevenção da doença de newcastle em galináceos
PL191551B1 (pl) Kompozycje immunogenne, plazmidy, zastosowania plazmidów, zestawy oraz szczepionki
WO1997048370A3 (en) Vaccines comprising synthetic genes
HUT71847A (en) Dna molecules encoding aminopeptidase enzymes, vectors and transgenic cells containing dna molecules, immunogenic polypeptides encoding by dna molecules, vaccines against helminth infections containing these peptides and process for the preparation ...
Fooks et al. Immunization of mice with plasmid DNA expressing the measles virus nucleoprotein gene
WO2001004280A3 (de) Impfstoff gegen infektionen mit lentiviren, wie dem felinen immunschwäche-virus der katze
FR2829498B1 (fr) Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins
Boyle et al. Influence of dose and route of inoculation on responses of chickens to recombinant fowlpox virus vaccines
WO1998052603A3 (en) An influenza enveloped dna vaccine
DE60239753D1 (de) Impfstoff gegen infektiöses lachsanämievirus
ZA941853B (en) Stimulation of immune response by viral protein
Roberti et al. Vaccination of rainbow trout against infectious hematopoietic necrosis (IHN) by using attenuated mutants selected by neutralizing monoclonal antibodies
AR023505A1 (es) Un vector de expresion que contiene una secuencia polinucleotidica que codifica en parte una glicoproteina de lyssavirus, polipeptidos y una composicion inmunogenica.
FR2825280B1 (fr) Vaccination contre le virus de l'immunodeficience feline
CY1107374T1 (el) Εμβολιο ιχθυος εναντι της piscirickettsia salmonis
Vogel Live Vaccines, Vector Vaccines and Virus-Like Particles
Kozlov et al. Comparison of adjuvant activities of glucosaminyl-muramyl dipeptide and of the gene coding for granulocyte-macrophage colony-stimulating factor in DNA immunization against herpes simplex virus

Legal Events

Date Code Title Description
FC Refusal